73779-38-1

Upstream product

• 1123-00-8 2-cyclopentylacetic acid 
• 766-00-7 2-cyclopentyl-ethanol 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 18928-94-4 (2-bromo-ethyl)-cyclopentane 
• 70895-14-6 4-(4-Chloro-phenyl)-1-(2-cyclopentyl-ethyl)-4-dimethylamino-cyclohexanol 
• 70895-14-6 4-(4-Chloro-phenyl)-1-(2-cyclopentyl-ethyl)-4-dimethylamino-cyclohexanol 
• 1447728-72-4 C₂₀H₂₂O₂Se 
• 1447728-78-0 C₁₄H₁₇BrO₂ 
• 1447728-83-7 C₂₂H₂₄O₄ 
• 1447728-98-4 C₂₀H₂₄O₃ 
• 1447729-04-5 C₁₄H₁₇BrO₂Zn 

Relevant academic research and scientific papers

NON-PEPTIDIC NEUROPEPTIDE Y RECEPTOR MODULATORS

The invention provides compounds that are modulators of neuropeptide Y (NPY) receptors, which can be selective inhibitors of NPY receptor Y2R. NPY receptor modulatory compounds are of the general formula Ar2-Y-Ar1-W-Ar3, wherein the variables are as defined herein. Compounds of the invention can be used for treatment of malconditions in patients wherein modulation of an NPY receptor is medically indicated, for example including drug or alcohol abuse, anxiety disorders, depression, stress-related disorders, neurological disorders, nerve degeneration, osteoporosis or bone loss, sleep/wake disorders, cardiovascular diseases, obesity, anorexia, inovulation, fertility disorders, angiogenesis, cell proliferation, learning and memory disorders, migraine and pain.

Preparation and palladium-mediated cross-coupling of α- benzoyloxyalkylzinc bromides

Here we report a two-step preparation protocol of α- benzoyloxyalkylzinc bromides from α-benzoyloxyalkyl selenides, and their application to palladium-catalyzed cross-coupling reactions with aryl and vinyl iodides. The developed method effectively provides a variety of benzoyl-protected benzylic and allylic alcohol derivatives through the formation of C(sp3)-C(sp2) bonds without affecting various polar functional groups.

NONAQUEOUS SOLVENT FOR ELECTRICAL STORAGE DEVICE

Provided is a nonaqueous solvent for an electrical storage device, including a fluorine-containing, cyclic, saturated hydrocarbon represented by the following general formula (1) and having a structure obtained by introducing one or two substituents R into a cyclopentane ring: in the general formula (1), R is represented by CnX2n+1, n represents an integer of 1 or more, at least one of the 2n+1 X's represents F, and the other X's each represent H.

OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION

ABSTRACT The present invention provides a oxazole compound represented by Formula (1), or a salt thereof: wherein R1 is an aryl group which may have one or more substituents; R2 is an aryl group or a nitrogen atom-containing heterocyclic group each of which may have one or more substituents; and W is a divalent group represented by -Y1-A1- or -Y2-C(=O)- wherein Y1 is a group such as -C(=O)-, A1 is a group such as a lower alkylene group, and Y2 is a group such as a piperazinediyl group. The oxazole compound has a specific inhibitory action against phosphodiesterase 4.

Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia

A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, wherein: Q is selected from the group consisting of: and L is selected from the group consisting of: or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, are useful in treating diseases, disorders, or conditions such as metabolic syndrome and dyslipidemia.